Regulatory Affairs Outsourcing

Similar documents
Take a Course of Action.

POLICY OFFICE OF PHARMACEUTICAL QUALITY

Stay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know

Guidance for Industry and Food and Drug Administration Staff

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review

Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit

New Requirement for Electronic Submission of DMFs

Accelerated Translational Incubator Pilot (ATIP) Program. Frequently Asked Questions. ICTR Research Navigators January 19, 2017 Version 7.

What's New with the 356h Form? Beth Duvall Associate Director for Regulatory Affairs Office of New Drugs Center for Drug Evaluation and Research

Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

FDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations

Received an RTA Deficiency List or AI Letter? Now What?

Confronting the Challenges of Rare Disease:

New federal requirements for posting of clinical trials information

The 3E Principle of Outsourcing

Call for proposals on platform technologies: Frequently asked questions (FAQs) - 1

How to Get the Business Started?

Vertex Investigator-Initiated Studies Program Overview

Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center

AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES

FISCAL YEAR FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-1044) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS

Retrospective Chart Review Studies

EXAM PREPARATION GUIDE

CRCE Exam Study Manual Update for 2017

Standards and Medical Device Regulation Roundtable. Seoul South Korea. 21 October ASTM International

At PRI, we re all about focus.

GDUFA II: Requests for Reconsideration

Life Sciences Tax Incentive Program

Clinical Research Professionals

POLICY AND PROCEDURES. Office of Generic Drugs and Office of Pharmaceutical Quality. Table of Contents

FDA s ectd Mandate for 2017: Latest Developments. Phillip DeNoble, PharmD, B.Sc.

FY19 Accountability Court Grant Application Webinar COUNCIL OF ACCOUNTABILITY COURT JUDGES (CACJ)

FDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, Elizabeth Hillebrenner, MSE OIR/CDRH/FDA

Statement of Guidance: Outsourcing Regulated Entities

FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV

ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer

ClinicalTrials.gov workshop

Louisiana State Nurses Association Primary Nurse Planner: Roles and Functions

IMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats

Pre-Submissions and Meetings with FDA Staff

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

BE-595M Homework Assignment Due: 3/3/08

Assurance at Country Level: External Audit of Grant Recipients. High Impact Asia Regional Report. GF-OIG August 2013

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

ACC Privacy Policy. Policy Statement. Objective. Scope. Policy system. Policy standards. Collection

Administrative Burden of Research Compliance

Expert Review Panel for Diagnostics - Lessons Learnt

FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice

lobal armonised ubmission ransport tandard (GHSTS) OECD Project on Harmonisation of Electronic Submissions of Pesticide Dossiers

FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM

Sector Specific. Statutory Quality Assurance Guidelines. developed by QQI for Designated Awarding Bodies. Designated Awarding Bodies (DABs)

Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements

COMPLIANCE PLAN PRACTICE NAME

Assurance at Country Level: External Audit of Grant Recipients. High Impact Africa 2 Regional Report. GF-OIG August 2013

IMPROVING YOUR CLINICAL TRIAL & ENHANCING THE PATIENT EXPERIENCE

Establishment of the FDA Office of Patient Affairs

Occupational Health and Safety Employee Handbook 2011

1 The EU Harmonised technical ectd guidance version 4.0

DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008

Regulatory Compliance. Operations and Systems Outsourcing: Compliance Considerations for Broker-Dealers.

THE ASCENSION HEALTH CORPORATE RESPONSIBILITY PROGRAM A MISSION BASED ON VALUES AND ETHICS

The Vision for the Future

NSERC Management Response: Evaluation of NSERC s Discovery Program

BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

September 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Multi-Year Accessibility Action Plan

Request for Proposals: Non-Profit Housing Corporation Property Acquisition and Renovation

Program Plan For the Energy Efficiency and Renewable Energy Technology Account Under New York s Clean Air Interstate Rules (CAIR)

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Request for Qualifications (RFQ) RFQ203: Architectural Services for Lab Design renovations

Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions

Standard Operating Procedures

Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission

DARPA 101. Tom McCreery and Wayne Bryden.

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

Novartis Business Services HR University Relations. Regulatory Affairs. Graduate & Postgraduate Program

Strategies for attracting healthcare venture capital

NASACT Benchmarking and Related Consulting Services RFP Questions and Answers

1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements

Engaging Global Stakeholders to Expand Access to the LNG-IUS. Sally Stephens, Senior VP, Corporate Development, Medicines360

COMMISSION IMPLEMENTING REGULATION (EU)

Report of the Auditor General of Canada to the House of Commons

Understanding PASRR Categorical Decisions

Case: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A

Regulatory Submissions Trends Survey 2002 Ellen Semple Date received (in revised form): 18th March, 2003

VETERANS TRUST FUND GRANT ANNOUNCEMENT

EDQM roadmap for electronic submissions

LCDR Kemi Asante, PharmD, RAC Health Science Policy Analyst Office of Prescription Drug Promotion CDER FDA

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

AN ACT. Be it enacted by the General Assembly of the State of Ohio:

NAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES

PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS

REQUEST FOR PROPOSALS SELECTION OF EXECUTIVE SEARCH FIRM

Auditing of Clinical Trials

RFP No. FY2017-ACES-02: Advancing Commonwealth Energy Storage Program Consultant

Department of Defense DIRECTIVE

IU ClinicalTrials.gov: Compliance Program Plan

Transcription:

Regulatory Affairs Outsourcing

INTRODUCTION The FDA Group, LLC (The FDA Group) is an organization that utilizes a proprietary talent selection process of former FDA & industry professionals, amplified by a corporate culture of responsiveness and execution. Headquartered in Westborough, Massachusetts, The FDA Group has more than 445 specialists (65 of whom are former FDA Investigators) across 42 states. Why is The FDA Group in business? We are in business to provide our clients with a world-class service experience that assures them and their stakeholders that their products are brought to market expeditiously are of the highest quality through a quality system that is compliant and efficient. How does The FDA Group do it? Through our proprietary talent selection process and deep-rooted corporate culture built upon 25 fundamentals. These fundamentals are the heartbeat of our organization and focus on four primary concepts: Core Values: Ten values that form the cornerstone of our success. Focus on Service: These client-centered habits ensure you receive an extraordinary service experience. The Collaborative Way: These practices transform our network of professionals into a powerful extension of your quality team. Personal Effectiveness: These behaviors help us achieve greater personal, and by extension, organizational success. Click here to learn how our 25 fundamentals can help you achieve extraordinary results. What does The FDA Group do? The FDA Group is a global leader in GxP auditing, remediation support, quality system resourcing, regulatory affairs, and expert witness services. Visit our Services page here to learn more. 2

REGULATORY AFFAIRS OUTSOURCING The regulatory landscape is constantly changing with new initiatives and guidances from the FDA. Do you feel that the FDA does not understand your development program as well as you would like them to? Are you worried that their expectations keep changing? Are you concerned that your development timelines and costs will be negatively impacted by not being able to reach a reasonable agreement with the FDA? Imagine if you had a team with the experience and expertise in interacting with US FDA and other global regulatory agencies that could help you bring your novel product idea from concept to an approved product that can be commercialized. The entire process from the first call to the agency to the final approval of your application is a multi-disciplinary and complex process. Our team of former FDA and industry experts can help you navigate the regulatory challenges in bringing your idea for a novel product in front of the regulatory agency to obtain approval to market. You will obtain approval for your product staying within budget and in the shortest possible time thus maximizing the return on investment for your company. When we decided to pursue FDA approval for a new medical device, we did not know where to begin. Luckily, some cursory research led me to a call with The FDA Group, LLC. They did an excellent job of explaining the process and keeping me well informed every step of the way. They completed the project early and came in under budget. I would highly recommend The FDA Group, LLC for all your regulatory needs. Are you concerned that your regulatory submission is not complete and properly organized and will not be accepted by the FDA at the first attempt? A refusal to receive (RTR) or a refuse to accept (RTA) for an application can have a significant cost in terms of both money and time (delays in product approval and launch) for your development program and your company. Can you afford this preventable cost to your company? What if you had a team of former FDA and industry experts who understood the importance of time and money to your development program? We always emphasize a right-first-time approach to ensure you stay within budget and timeline. Our experts are meticulously selected to provide a breadth and depth of experience that matches your needs. These experts have a thorough understanding of the regulatory requirements for a complete and well-organized package for FDA submission ensuring right-first-time. Another benefit is a shortened review cycle thus saving valuable time. A good package tells the agencies that you understand your obligations and are serious about complying with their regulations, which builds a favorable impression for your company. You will experience overall faster approval time and prevent unnecessary penalties and other costs associated with sub-standard submissions. Finally, you will prevent delays in bringing product to market and you will maximize returns on your investment. 3

I highly recommend contacting The FDA Group, LLC if your company is in need of regulatory consulting. They have successfully matched the right consultant to the right issue for our business many times. From day-to-day Regulatory Affairs questions and training to significant issues such as recall management and 483 responses, The FDA Group has a pool of consultants to pull from that can assist you both expeditiously and professionally. The FDA Group offers a team of Regulatory Affairs professionals who have vast experience working with the US FDA. Our regulatory expertise ensures that regulatory strategies and alternatives are considered at every step to help you gain product registration. The FDA Group will work with you in both pre- and post-marketing drug safety regulations, regulatory filings, marketing authorization applications, variations and renewals and carefully developed due diligence strategies. Our Regulatory Affairs services include: Review of client technical dossiers and developmental plans Research and interpretation of regulations Determination of regulatory status Pre-submission review of technical documents Critical writing and review of documentation Clinical trial applications and notifications for Investigational New Drugs (IND), Investigational Device Exemptions (IDE), etc.) Marketing Application Support for New Drug Applications (NDA), Biologics License Applications (BLA), Abbreviated New Drug Applications (ANDA), 510(k) Approvals, Premarket Approval (PMA), etc.) Orphan Drug, Treatment Use, and ANDA Suitability petitions The FDA Group s experience encompasses US FDA clinical trial applications, and registrations of new chemical and biological entities, as well as those products containing established pharmaceutical ingredients (generics and 505(b)(2) products). We develop high-level regulatory strategies to expedite products through clinical trials and into the market, and regularly represent our clients in meetings with the US FDA. The FDA Group can manage the entire registration process for new medicinal products as well as for generic products. We have extensive experience writing Drug Master Files for product registrations. The FDA Group s Regulatory Operations supports the production of submissions in both paper ( old and CTD formats) and electronic formats. Whether you are submitting an original IND, NDA or ANDA, or an amendment, supplement, or variation to an existing application, or converting an existing application to ectd format, we can publish and deliver an FDA/ICH-compliant submission to meet your needs. 4

In the ever changing world of regulatory submissions, we work with industry leaders to stay at the forefront of ectd requirements. By using highly qualified and experienced staff to perform the e- publishing we can offer affordable e-submissions to our client companies, regardless of the size of their company. Our publishing team works closely with the authors to ensure documents are written using industry templates with the appropriate granularity, and to ensure formatting consistency across the dossier. Throughout all stages of submission preparation, consideration is given to the potential lifecycle management of the application to ensure that accommodations to future changes and amendments can be made with little or no disruption to the overall message of the application. The FDA Group prepares all major regulatory submissions and provides extensive quality control review for all trial related documentation, such as: Regulatory Agency and IRB/EC submissions Procurement of Import/Export license, as applicable Initial submissions, amendments, notifications, and closeout submissions Working as a collaborative team, our regulatory specialists coordinate all aspects of your trial's document collection and submissions, including: Manage all regulatory documentation as part of the start-up, conduct, and close-out phases Coordinates clinical trial application filings to regulatory agencies Ensures submissions comply with regulations Manages submissions and document storage processes Stays abreast of all regulations to ensure documentation compliance Our team of experienced regulatory scientists can write the nonclinical, clinical and CMC sections in CTD and traditional format for your new drug and biologic applications. We have extensive experience writing Drug Master Files for product registrations. 5